A Phase 2 interventional study of ibrutinib and venetoclax in Leukemia, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 46 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by enrollment, is one of 14 that started in 2016, is one of 43 in phase 2, and was the 45th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 14 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 323 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie: 3 open now, 11 under way, 2 of them phase 3. Of 38 finished, 18 (47%) have results posted.
Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 2nd largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2016, is one of 11 in phase 2, and was the 28th registered.
AbbVie’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2004.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AbbVie’s 51 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
This study's enrollment of 323 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
First submitted after Pharmacyclics LLC. became part of AbbVie.
Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 420 mg of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment (ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule) for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
Drug: ibrutinib · Drug: venetoclax
Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase). Participants with confirmed uMRD are randomized to receive ibrutinib 420 mg orally once daily on a continuous schedule until MRD-positive relapse, disease progression (PD), or unacceptable toxicity. After MRD-positive relapse or disease progression (PD) by iwCLL criteria, participants can reintroduce 400 mg venetoclax with a 5-week ramp up. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.
Drug: ibrutinib · Drug: venetoclax
Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase). Participants with confirmed uMRD are randomized to receive placebo orally once daily on a continuous schedule until MRD-positive relapse, PD or unacceptable toxicity. If MRD-positive relapse or PD is confirmed after restaging per iwCLL criteria, participants can first reintroduce oral daily ibrutinib with the option of subsequently reintroducing 400 mg venetoclax with a 5-week ramp up, if subsequent disease relapse per iwCLL criteria occurs after ibrutinib reintroduction. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.
Drug: ibrutinib · Drug: venetoclax · Drug: Placebo
Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase). Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. In case of confirmed PD after restaging per iwCLL criteria, participants can continue ibrutinib and reintroduce venetoclax treatment. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.
Drug: ibrutinib · Drug: venetoclax
Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase). Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. Venetoclax was allowed for administration up to 2 years cumulatively from first dose started in the pre-randomization phase to last dose in the randomization phase.
Drug: ibrutinib · Drug: venetoclax
ibrutinib administered orally once daily (three 140 mg capsules)
venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
placebo capsules to match ibrutinib administered orally once daily
MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants
DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia \[IWCLL\] criteria \[Halleck et al\]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time.
Time frame: 1 year after randomization
FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate
CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.
Time frame: From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months.
MRD Cohort: CRR (CR/CRi Rate)
CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
Time frame: From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
MRD Cohort: Overall Response Rate (ORR)
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
Time frame: From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
MRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of 67.0 months study follow-up, the Kaplan-Meier estimate of DOR at 42 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
Time frame: From initial documentation of a response until PD or death from any cause, whichever occurs first, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
MRD Cohort: MRD-Negativity Rate
MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
Time frame: From randomization date until before any subsequent antineoplastic therapy, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.
Time frame: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
Time frame: From the first dose of ibrutinib to the first confirmed PD or death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD: Randomized to Ibrutinib=69.1 months; Confirmed uMRD: Randomized to Placebo=67.4 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib=47.9 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax=47.9 months.
Time frame: From the first dose of ibrutinib to time of death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
MRD Cohort: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.
Time frame: From first dose until 30 days following last dose of study drug. Overall median treatment duration for the MRD cohort was 45.1 months.
FD Cohort: ORR
ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.
Time frame: From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months.
FD Cohort: DOR at 60 Months Landmark Time
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 60 months landmark time was presented.
Time frame: From initial documentation of a response until PD or death from any cause, whichever occurs first, for a median follow-up of 69.0 months.
FD Cohort: MRD Negativity Rate
MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.
Time frame: From randomization date until before any subsequent antineoplastic therapy, for a median follow-up of 69.0 months.
FD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 66 months landmark time was presented.
Time frame: From the first dose of ibrutinib to the first confirmed PD or death, for an median follow-up of 69.0 months.
FD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 66 months landmark time was presented.
Time frame: From the first dose of ibrutinib to time of death, for a median follow-up of 69.0 months.
FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.
Time frame: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
FD Cohort: Percentage of Participants With TEAEs, Treatment-Emergent SAEs, and Discontinuations Due to TEAEs
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.
Time frame: From first dose until 30 days following last dose of study drug. Overall median treatment duration for the FD cohort was 13.8 months.
MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Time to Cmax (Tmax); Time of Last Measurable Concentration (Tlast); Terminal Elimination Half-Life (t1/2,Term)
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Area Under the Plasma Concentration-Time Curve (AUC) Over the Last 24-hour Dosing Interval (AUC0-24h); AUC From Time Zero to the Time of Last Quantifiable Concentration (AUClast)
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F
Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
This study was conducted at 39 centers in the United States (US), Australia, New Zealand, Spain, and Italy.
| Milestone | Fixed Duration (FD) Cohort: All Treated | Minimal Residual Disease (MRD) Cohort: All Treated |
|---|---|---|
| Started | 159 | 164 |
| Mrd cohort/ not randomized | 0 | 15 |
| Mrd cohort/ confirmed umrd: randomized to ibrutinib (blinded) | 0 | 43 |
| Mrd cohort/ confirmed umrd: randomized placebo (blinded) | 0 | 43 |
| Mrd cohort/umrd not confirmed: randomized to ibrutinib (open-label) | 0 | 31 |
| Mrd cohort/umrd not confirmed: randomized ibrutinib + venetoclax (open-label) | 0 | 32 |
| Completed | 133 | 150 |
| Not completed | 26 | 14 |
| Withdrew: Death | 7 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 12 | 8 |
| Withdrew: Other, not specified | 6 | 3 |
DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia \[IWCLL\] criteria \[Halleck et al\]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time.
| percentage of participants | MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) |
|---|---|---|
| MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants | 100.0 (100.0 to 100.0) | 95.3 (82.7 to 98.8) |
CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.
| percentage of participants | FD Cohort, Non-Del 17p Population | Fixed Duration (FD) Cohort: All Treated |
|---|---|---|
| FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate | 58.1 (49.8 to 66.4) | 57.2 (49.5 to 64.9) |
CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
| percentage of participants | MRD Cohort: All Treated | MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax |
|---|---|---|---|---|---|
| MRD Cohort: CRR (CR/CRi Rate) | 66.5 (59.2 to 73.7) | 79.1 (66.9 to 91.2) | 65.1 (50.9 to 79.4) | 77.4 (62.7 to 92.1) | 56.3 (39.1 to 73.4) |
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
| percentage of participants | MRD Cohort: All Treated | MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax |
|---|---|---|---|---|---|
| MRD Cohort: Overall Response Rate (ORR) | 97.0 (94.3 to 99.6) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of 67.0 months study follow-up, the Kaplan-Meier estimate of DOR at 42 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
| percentage of participants | MRD Cohort: All Treated | MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax |
|---|---|---|---|---|---|
| MRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time | 93.5 (88.2 to 96.4) | 97.6 (84.3 to 99.7) | 93.0 (79.7 to 97.7) | 96.7 (78.6 to 99.5) | 93.2 (75.5 to 98.3) |
MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
| percentage of participants | MRD Cohort: All Treated | MRD Cohort/uMRD Not Confirmed: All Participants | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax |
|---|---|---|---|---|
| PB or BM | 81.7 (75.8 to 87.6) | 65.1 (53.3 to 76.9) | 51.6 (34.0 to 69.2) | 78.1 (63.8 to 92.4) |
| BM | 77.4 (71.0 to 83.8) | 55.6 (43.3 to 67.8) | 41.9 (24.6 to 59.3) | 68.8 (52.7 to 84.8) |
| PB | 79.9 (73.7 to 86.0) | 60.3 (48.2 to 72.4) | 48.4 (30.8 to 66.0) | 71.9 (56.3 to 87.5) |
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.
| percentage of participants | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in) | 90.0 |
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.
| percentage of participants | MRD Cohort: All Treated | MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax |
|---|---|---|---|---|---|
| MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time | 90.9 (85.1 to 94.5) | 97.6 (84.3 to 99.7) | 88.2 (73.9 to 94.9) | 93.3 (75.9 to 98.3) | 93.2 (75.5 to 98.3) |
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD: Randomized to Ibrutinib=69.1 months; Confirmed uMRD: Randomized to Placebo=67.4 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib=47.9 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax=47.9 months.
| percentage of participants | MRD Cohort: All Treated | MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax |
|---|---|---|---|---|---|
| MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time | 98.0 (94.0 to 99.4) | 97.6 (84.3 to 99.7) | 100.0 (100.0 to 100.0) | 96.7 (78.6 to 99.5) | 100.0 (100.0 to 100.0) |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.
| percentage of participants | MRD Cohort: All Treated | MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) | MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib | MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax |
|---|---|---|---|---|---|
| Any TEAE | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Any Grade >=3 TEAE | 75.6 | 83.7 | 72.1 | 71.0 | 78.1 |
| Any Ibrutinib (Ibr)-Related TEAE | 95.7 | 97.7 | 93.0 | 96.8 | 93.8 |
| Any Grade >=3 Ibrutinib-Related TEAE | 57.9 | 55.8 | 51.2 | 61.3 | 62.5 |
| Any Venetoclax (Ven)-Related TEAE | 81.1 | 88.4 | 76.7 | 80.6 | 96.9 |
| Any Grade >=3 Venetoclax-Related TEAE | 44.5 | 51.2 | 34.9 | 45.2 | 56.3 |
| Any TEAE Leading to Ibr or Ven Discontinuation | 15.9 | 16.3 | 0 | 9.7 | 12.5 |
| Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only | 10.4 | 14.0 | 0 | 9.7 | 3.1 |
| Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only | 1.2 | 2.3 | 0 | 0 | 0 |
| Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven | 4.3 | 0 | 0 | 0 | 9.4 |
| Any TEAE Leading to Ibr or Ven Dose Reduction | 26.2 | 23.3 | 25.6 | 25.8 | 34.4 |
| Any TEAE Leading to Ibr Only Dose Reduction | 16.5 | 16.3 | 11.6 | 19.4 | 25.0 |
| Any TEAE Leading to Ven Only Dose Reduction | 4.9 | 2.3 | 11.6 | 0 | 3.1 |
| Any TEAE Leading to Both Ibr and Ven Dose Reduction | 4.9 | 4.7 | 2.3 | 6.5 | 6.3 |
| Any SAE | 34.1 | 34.9 | 32.6 | 41.9 | 37.5 |
| Any Grade >= 3 SAE | 28.7 | 32.6 | 27.9 | 32.3 | 28.1 |
| Any SAE Related to Ibr or Ven | 20.1 | 18.6 | 14.0 | 25.8 | 21.9 |
| Any Ibr-related SAE | 17.1 | 14.0 | 11.6 | 22.6 | 18.8 |
| Any Ven-related SAE | 6.7 | 4.7 | 7.0 | 12.9 | 6.3 |
| Fatal TEAE | 1.2 | 2.3 | 0 | 3.2 | 0 |
| Major Hemorrhage TEAE | 2.4 | 2.3 | 0 | 3.2 | 6.3 |
| Grade >= 3 Major Hemorrhage TEAE | 1.8 | 2.3 | 0 | 3.2 | 3.1 |
| Major Hemorrhage SAE | 2.4 | 2.3 | 0 | 3.2 | 6.3 |
ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.
| percentage of participants | FD Cohort, Non-Del 17p Population | Fixed Duration (FD) Cohort: All Treated |
|---|---|---|
| FD Cohort: ORR | 95.6 (92.1 to 99.0) | 96.2 (93.3 to 99.2) |
Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 60 months landmark time was presented.
| percentage of participants | FD Cohort, Non-Del 17p Population | Fixed Duration (FD) Cohort: All Treated |
|---|---|---|
| FD Cohort: DOR at 60 Months Landmark Time | 63.6 (54.4 to 71.4) | 60.5 (52.0 to 68.0) |
MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.
| percentage of participants | FD Cohort, Non-Del 17p Population | Fixed Duration (FD) Cohort: All Treated |
|---|---|---|
| BM or PB | 78.7 (71.8 to 85.6) | 78.6 (72.2 to 85.0) |
| BM | 61.8 (53.6 to 69.9) | 59.7 (52.1 to 67.4) |
| PB | 76.5 (69.3 to 83.6) | 76.7 (70.2 to 83.3) |
PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 66 months landmark time was presented.
| percentage of participants | FD Cohort, Non-Del 17p Population | Fixed Duration (FD) Cohort: All Treated |
|---|---|---|
| FD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time | 63.2 (54.1 to 71.0) | 60.2 (51.7 to 67.7) |
OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 66 months landmark time was presented.
| percentage of participants | FD Cohort, Non-Del 17p Population | Fixed Duration (FD) Cohort: All Treated |
|---|---|---|
| FD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time | 96.9 (92.1 to 98.8) | 96.1 (91.4 to 98.2) |
TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.
| percentage of participants | Fixed Duration (FD) Cohort: All Treated |
|---|---|
| FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in) | 94.1 |
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.
| percentage of participants | Fixed Duration (FD) Cohort: All Treated |
|---|---|
| Any TEAE | 99.4 |
| Any Grade >=3 TEAE | 62.3 |
| Any Ibrutinib (Ibr)-Related TEAE | 92.5 |
| Any Grade >=3 Ibrutinib-Related TEAE | 44.7 |
| Any Venetoclax (Ven)-Related TEAE | 84.3 |
| Any Grade >=3 Venetoclax-Related TEAE | 45.3 |
| Any TEAE Leading to Ibr or Ven Discontinuation | 5.0 |
| Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only | 3.1 |
| Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only | 0 |
| Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven | 1.9 |
| Any TEAE Leading to Ibr or Ven Dose Reduction | 20.8 |
| Any TEAE Leading to Ibr Only Dose Reduction | 5.7 |
| Any TEAE Leading to Ven Only Dose Reduction | 11.3 |
| Any TEAE Leading to Both Ibr and Ven Dose Reduction | 3.8 |
| Any SAE | 23.3 |
| Any Grade >= 3 SAE | 20.1 |
| Any SAE Related to Ibr or Ven | 13.8 |
| Any Ibr-related SAE | 11.9 |
| Any Ven-related SAE | 8.8 |
| Fatal TEAE | 0.6 |
| Major Hemorrhage TEAE | 1.9 |
| Grade >= 3 Major Hemorrhage TEAE | 1.3 |
| Major Hemorrhage SAE | 1.3 |
| ng/mL | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax) | 88.5 ± 74.3 |
| hours | MRD Cohort: All Treated |
|---|---|
| tmax | 2.00 (0.970 to 7.00) |
| tlast | 24.0 (5.75 to 24.0) |
| t1/2term | 5.30 (1.47 to 10.5) |
| ng*h/mL | MRD Cohort: All Treated |
|---|---|
| AUC0-24h | 504 ± 76.3 |
| AUClast | 480 ± 78.5 |
| 1/h | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz) | 0.132 ± 44.5 |
| L/h | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F) | 833 ± 90.9 |
| ng/mL | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax | 3034 ± 56.3 |
| hours | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax | 6.00 (0.00 to 8.08) |
| ng*h/mL | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h | 48993 ± 66.2 |
| L/h | MRD Cohort: All Treated |
|---|---|
| MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F | 8.16 ± 69.7 |
Collected over From first dose until 30 days following last dose of study drug. Overall median treatment duration was 45.1 months for the MRD cohort and 13.8 months for the FD cohort.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FD Cohort: Pre-Dose | 0/159 (0%) | 1/159 (0.6%) | 1/159 (0.6%) |
| MRD Cohort: Pre-Dose | 0/164 (0%) | 2/164 (1.2%) | 1/164 (0.6%) |
| FD Cohort: All Participants | 5/159 (3.1%) | 37/159 (23.3%) | 156/159 (98.1%) |
| MRD Cohort: All Participants | 3/164 (1.8%) | 63/164 (38.4%) | 163/164 (99.4%) |
| MRD Cohort: Confirmed uMRD (IbrVen->Ibr) | 1/43 (2.3%) | 15/43 (34.9%) | 43/43 (100%) |
| MRD Cohort: Confirmed uMRD (IbrVen->Pbo) | 0/43 (0%) | 14/43 (32.6%) | 43/43 (100%) |
| MRD Cohort: uMRD Not Confirmed (IbrVen->Ibr) | 1/31 (3.2%) | 13/31 (41.9%) | 31/31 (100%) |
| MRD Cohort: uMRD Not Confirmed (IbrVen->IbrVen) | 0/32 (0%) | 12/32 (37.5%) | 32/32 (100%) |
| FD Cohort: Reintroduced Ibrutinib | 2/18 (11.1%) | 6/18 (33.3%) | 14/18 (77.8%) |
| FD Cohort: Reintroduced Ibr+Ven | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| MRD Cohort: Reintroduced Ibrutinib | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| MRD Cohort: Reintroduced Ven + Continued Ibr | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | FD Cohort: Pre-Dose | MRD Cohort: Pre-Dose | FD Cohort: All Participants | MRD Cohort: All Participants | MRD Cohort: Confirmed uMRD (IbrVen->Ibr) | MRD Cohort: Confirmed uMRD (IbrVen->Pbo) | MRD Cohort: uMRD Not Confirmed (IbrVen->Ibr) | MRD Cohort: uMRD Not Confirmed (IbrVen->IbrVen) | FD Cohort: Reintroduced Ibrutinib | FD Cohort: Reintroduced Ibr+Ven | MRD Cohort: Reintroduced Ibrutinib | MRD Cohort: Reintroduced Ven + Continued Ibr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CELLULITISInfections and infestations | 0/159 | 0/164 | 4/159 | 1/164 | 1/43 | 0/43 | 0/31 | 0/32 | 0/18 | 0/11 | 1/7 | 0/2 |
| PNEUMONIAInfections and infestations | 0/159 | 0/164 | 3/159 | 9/164 | 3/43 | 1/43 | 3/31 | 2/32 | 0/18 | 0/11 | 0/7 | 0/2 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/159 | 0/164 | 1/159 | 4/164 | 0/43 | 3/43 | 0/31 | 0/32 | 0/18 | 0/11 | 0/7 | 0/2 |
| NEUTROPENIABlood and lymphatic system disorders | 0/159 | 0/164 | 1/159 | 2/164 | 0/43 | 0/43 | 2/31 | 0/32 | 0/18 | 0/11 | 0/7 | 0/2 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/159 | 0/164 | 0/159 | 3/164 | 1/43 | 0/43 | 2/31 | 0/32 | 0/18 | 0/11 | 0/7 | 0/2 |
| ANGINA PECTORISCardiac disorders | 0/159 | 0/164 | 0/159 | 0/164 | 0/43 | 0/43 | 0/31 | 0/32 | 1/18 | 0/11 | 0/7 | 0/2 |
| OESOPHAGEAL SPASMGastrointestinal disorders | 0/159 | 0/164 | 0/159 | 0/164 | 0/43 | 0/43 | 0/31 | 0/32 | 1/18 | 0/11 | 0/7 | 0/2 |
| PYREXIAGeneral disorders | 0/159 | 0/164 | 0/159 | 1/164 | 0/43 | 0/43 | 0/31 | 1/32 | 1/18 | 0/11 | 0/7 | 0/2 |
| BRONCHITISInfections and infestations | 0/159 | 0/164 | 1/159 | 0/164 | 0/43 | 0/43 | 0/31 | 0/32 | 1/18 | 0/11 | 0/7 | 0/2 |
| COVID-19 PNEUMONIAInfections and infestations | 0/159 | 0/164 | 0/159 | 1/164 | 1/43 | 0/43 | 0/31 | 0/32 | 1/18 | 0/11 | 0/7 | 0/2 |
| Event | FD Cohort: Pre-Dose | MRD Cohort: Pre-Dose | FD Cohort: All Participants | MRD Cohort: All Participants | MRD Cohort: Confirmed uMRD (IbrVen->Ibr) | MRD Cohort: Confirmed uMRD (IbrVen->Pbo) | MRD Cohort: uMRD Not Confirmed (IbrVen->Ibr) | MRD Cohort: uMRD Not Confirmed (IbrVen->IbrVen) | FD Cohort: Reintroduced Ibrutinib | FD Cohort: Reintroduced Ibr+Ven | MRD Cohort: Reintroduced Ibrutinib | MRD Cohort: Reintroduced Ven + Continued Ibr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 0/159 | 0/164 | 99/159 | 119/164 | 34/43 | 28/43 | 23/31 | 28/32 | 3/18 | 4/11 | 2/7 | 2/2 |
| NAUSEAGastrointestinal disorders | 0/159 | 0/164 | 68/159 | 80/164 | 21/43 | 20/43 | 20/31 | 12/32 | 1/18 | 2/11 | 0/7 | 1/2 |
| NEUTROPENIABlood and lymphatic system disorders | 0/159 | 0/164 | 65/159 | 71/164 | 24/43 | 15/43 | 12/31 | 14/32 | 0/18 | 0/11 | 0/7 | 0/2 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/159 | 0/164 | 52/159 | 82/164 | 23/43 | 20/43 | 17/31 | 16/32 | 2/18 | 1/11 | 1/7 | 0/2 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/159 | 0/164 | 39/159 | 73/164 | 21/43 | 22/43 | 14/31 | 11/32 | 2/18 | 2/11 | 1/7 | 0/2 |
| ABDOMINAL PAINGastrointestinal disorders | 1/159 | 0/164 | 13/159 | 28/164 | 8/43 | 10/43 | 2/31 | 6/32 | 2/18 | 0/11 | 0/7 | 1/2 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 1/159 | 0/164 | 16/159 | 30/164 | 10/43 | 4/43 | 6/31 | 7/32 | 2/18 | 1/11 | 0/7 | 1/2 |
| VOMITINGGastrointestinal disorders | 0/159 | 0/164 | 33/159 | 42/164 | 13/43 | 6/43 | 7/31 | 11/32 | 0/18 | 0/11 | 0/7 | 1/2 |
| COVID-19Infections and infestations | 0/159 | 0/164 | 8/159 | 29/164 | 14/43 | 13/43 | 2/31 | 0/32 | 3/18 | 2/11 | 3/7 | 1/2 |
| FATIGUEGeneral disorders | 0/159 | 0/164 | 39/159 | 56/164 | 14/43 | 21/43 | 10/31 | 7/32 | 1/18 | 1/11 | 0/7 | 0/2 |
| Age, Customized(Participants) | FD Cohort: All Treated | MRD Cohort: All Treated | Total |
|---|---|---|---|
| < 65 years | 114 | 123 | 237 |
| >= 65 years | 45 | 41 | 86 |
| Sex: Female, Male(Participants) | FD Cohort: All Treated | MRD Cohort: All Treated | Total |
|---|---|---|---|
| Female | 53 | 61 | 114 |
| Male | 106 | 103 | 209 |
| Ethnicity (NIH/OMB)(Participants) | FD Cohort: All Treated | MRD Cohort: All Treated | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 11 | 16 |
| Not Hispanic or Latino | 149 | 150 | 299 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Race (NIH/OMB)(Participants) | FD Cohort: All Treated | MRD Cohort: All Treated | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 3 | 5 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 3 |
| White | 147 | 147 | 294 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 9 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Sep 2016 to primary completion in Nov 2020, 49 months.
Results were first posted in Feb 2022, 1 year 3 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 49 months is below that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell →